We’re not intending to capture all possible patients, but those we think would make the best trial candidates so that we can ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

The aim of this research was to explore whether IL-18 can be a serological marker for the diagnosis of systemic-onset juvenile idiopathic arthritis (sJIA). A total of 23 sJIA patients (13 males, ...

Objective To develop an ultrasonographic image acquisition protocol and a joint-specific scoring system for synovitis with reference atlas in patients with juvenile idiopathic arthritis (JIA) and to ...

Some forms of arthritis can strike children or even infants. By far, the most common type of childhood arthritis is juvenile idiopathic arthritis, often simply called juvenile arthritis (JA). On ...

Fresenius Kabi's tocilizumab biosimilar Tyenne® is the first and only tocilizumab biosimilar to be launched in Canada and is ...

Dr Jyothi RaghuramSenior Consultant - Pediatrics & Pediatric Rheumatology, Aster Whitefield Hospital, Bengaluru is ...

Diagnosed with JIA as a teenager, Kyle has used poetry as a means to process the physical and emotional challenges of living with a chronic illness. His work delves into the complexities of daily life ...

Slower tapering of adalimumab (ADA) significantly reduces the risk for noninfectious uveitis (NIU) relapse among pediatric patients, particularly those with juvenile idiopathic arthritis ...

Arthritis isn't limited to old age—many young adults experience joint pain due to autoimmune or post-traumatic causes. Early ...

Juvenile idiopathic arthritis (JIA) is inflammatory arthritis that starts in children under 16. Most forms of JIA are due to an immune system malfunction. While the exact cause of this auto-immune ...

Mum raises £6,500 from marathon challenge for arthritis charities after eight-year-old daughter is diagnosed with the ...